Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
May 16 2024 - 4:05PM
Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim
Green, Chairman and Chief Executive Officer, and Jennifer Cote,
Chief Financial Officer, will be participating in the Benchmark
Healthcare House Call Virtual Conference on May 22nd, 2024, with a
live fireside chat scheduled for 9:00-9:40 am ET. The Company
will also be hosting one-on-one meetings with investors in
conjunction with the Conference.
To register for the presentation, or to schedule
a one-on-one meeting, please visit the Benchmark website at 2024
Benchmark Healthcare House Call Virtual Conference.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer,
manufacturer and seller of technologies, products and services that
enable fundamental advances in life science applications, including
research, pharmaceutical and therapy discovery, bio-production and
preclinical testing for pharmaceutical and therapy development. Our
customers range from renowned academic institutions and government
laboratories to the world’s leading pharmaceutical, biotechnology
and contract research organizations. With operations in North
America, Europe, and China, we sell through a combination of direct
and distribution channels to customers around the world. For
more information, please visit our website at
www.harvardbioscience.com
Company Contact:Harvard BioscienceJennifer
Cote, Chief Financial Officer(508) 893-3120
Investor Contacts:Three Part AdvisorsSandy
Martin / Erol Girgin / William ShelmireHBIO@threepa.com(214)
616-2207
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024